Merck & Co., Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Merck & Co., Inc. (MRK) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$14.08 billion for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-26.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2024-02-26
- Merck & Co., Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2022-12-31 was -$1.75B.
- Merck & Co., Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2022-09-30 was -$962.00M.
- Merck & Co., Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2022-06-30 was -$1.08B.
- Merck & Co., Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2022-03-31 was -$1.17B.
- Merck & Co., Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2023 was -$14.08B.
- Merck & Co., Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2022 was -$4.96B.
- Merck & Co., Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2021 was -$16.42B.
- Merck & Co., Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2020 was -$9.19B.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$14.08B 10-K · filed 2024-02-26 | |||
| 2022-12-31 | -$1.75B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$2.71B derived: sum of 2 quarters · filed 2024-02-26 | -$3.79B derived: sum of 3 quarters · filed 2024-02-26 | -$4.96B 10-K · filed 2024-02-26 |
| 2022-09-30 | -$962.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$2.04B derived: sum of 2 quarters · filed 2022-11-03 | -$3.21B 10-Q · filed 2022-11-03 | -$15.26B derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | -$1.08B derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | -$2.25B 10-Q · filed 2022-08-05 | -$14.30B derived: sum of 3 quarters · filed 2024-02-26 | -$15.36B derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | -$1.17B 10-Q · filed 2022-05-05 | -$13.22B derived: sum of 2 quarters · filed 2024-02-26 | -$14.28B derived: sum of 3 quarters · filed 2024-02-26 | -$16.91B derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | -$12.05B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$13.11B derived: sum of 2 quarters · filed 2024-02-26 | -$15.73B derived: sum of 3 quarters · filed 2024-02-26 | -$16.42B 10-K · filed 2024-02-26 |
| 2021-09-30 | -$1.06B derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$3.69B derived: sum of 2 quarters · filed 2022-11-03 | -$4.37B 10-Q · filed 2022-11-03 | -$9.07B derived: sum of 4 quarters · filed 2023-02-24 |
| 2021-06-30 | -$2.63B derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | -$3.31B 10-Q · filed 2022-08-05 | -$8.01B derived: sum of 3 quarters · filed 2023-02-24 | -$10.09B derived: sum of 4 quarters · filed 2023-02-24 |
| 2021-03-31 | -$686.00M 10-Q · filed 2022-05-05 | -$5.38B derived: sum of 2 quarters · filed 2023-02-24 | -$7.47B derived: sum of 3 quarters · filed 2023-02-24 | |
| 2020-12-31 | -$4.70B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | -$6.78B derived: sum of 2 quarters · filed 2023-02-24 | -$9.19B 10-K · filed 2023-02-24 | |
| 2020-09-30 | -$2.09B derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | -$4.50B 10-Q · filed 2021-11-05 | ||
| 2020-06-30 | -$2.41B 10-Q · filed 2021-08-09 | |||
| 2019-12-31 | -$2.53B 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |